切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2018, Vol. 12 ›› Issue (01) : 14 -18. doi: 10.3877/cma.j.issn.1674-0793.2018.01.004

所属专题: 文献

论著

雌激素受体β1在MDA-MB-231人乳腺癌细胞中高表达对雷诺昔芬抗肿瘤作用的影响
姜华1, 李梓雄1, 程林1, 王佳妮1, 黄勇1, 李玺1, 刘仁斌1,()   
  1. 1. 510630 广州,中山大学附属第三医院甲状腺乳腺外科
  • 收稿日期:2017-06-02 出版日期:2018-02-01
  • 通信作者: 刘仁斌
  • 基金资助:
    广东省医学科学技术研究基金资助项目(A2017506)

Anticancer activity of raloxifene impacted by high expression of ERβ1 in MDA-MB-231 cell

Hua Jiang1, Zixiong Li1, Lin Cheng1, Jiani Wang1, Yong Huang1, Xi Li1, Renbin Liu1,()   

  1. 1. Department of Breast and Thyroid Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2017-06-02 Published:2018-02-01
  • Corresponding author: Renbin Liu
  • About author:
    Corresponding author: Liu Renbin, Email:
引用本文:

姜华, 李梓雄, 程林, 王佳妮, 黄勇, 李玺, 刘仁斌. 雌激素受体β1在MDA-MB-231人乳腺癌细胞中高表达对雷诺昔芬抗肿瘤作用的影响[J/OL]. 中华普通外科学文献(电子版), 2018, 12(01): 14-18.

Hua Jiang, Zixiong Li, Lin Cheng, Jiani Wang, Yong Huang, Xi Li, Renbin Liu. Anticancer activity of raloxifene impacted by high expression of ERβ1 in MDA-MB-231 cell[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(01): 14-18.

目的

探究雷诺昔芬(RAL)对乳腺癌中过表达雌激素受体(ER)β1的MDA-MB-231细胞的抑制作用。

方法

用含ERβ1基因的HIV慢病毒转染乳腺癌MDA-MB-231细胞,获得稳定表达ERβ1的乳腺癌细胞株。采用RT-PCR法检测转染细胞中ERβ1 mRNA的表达水平,Western blotting法检测细胞中ERβ1蛋白的表达水平;各细胞亚型分别于0、1、10 μmol/L的RAL共培养48 h,观察RAL对ERβ1高表达细胞株及对照细胞株治疗作用的差异。

结果

HIV慢病毒转染后细胞绿色荧光表达效率达到90%以上;RT-PCR检测显示阳性转染组MDA-MB-231/ERβ1细胞中ERβ1 mRNA水平较阴性转染组提高了12.9倍(P<0.05);阳性转染组细胞中ERβ1蛋白水平也相应提高;细胞实验表明高浓度(10 μmol/L)的RAL对MDA-MB-231细胞有明显的增殖抑制作用,特别是对ERβ1高表达细胞株的抑制作用更加明显(F=9.273,P=0.015)。

结论

在乳腺癌MDA-MB-231细胞中,ERβ1高表达可以使细胞对RAL更加敏感。

Objective

To up-regulate ERβ1 mRNA in breast cancer cells, and to explore the inhibiting effect of raloxifene (RAL) on MDA-MB-231 cell which has the high expression of ERβ1.

Methods

We used HIV lentivirus containing ERβ1 gene to infect breast cancer cell line of MDA-MB-231, and established cell-line stably over-expressing ERβ1 gene. Fluorescence microscopy was used to show the transfected cells of which the eGFP was positive. Then we identified the ERβ1 gene expression on the levels of mRNA and protein by RT-PCR and Western blotting. All cell subtypes were cultured with increasing concentration of RAL (0, 1, 10 μmol/L) for 48 h, the difference of therapeutic effects among the MDA-MB-231/ERβ1, MDA-MB-231/eGFP and MDA-MB-231 were detected.

Results

Fluorescence microscopy showed that more than 90% of transfected cells by the HIV lentivirus were green fluorescence positive. RT-PCR test showed that the levels of ERβ1 mRNA in MDA-MB-231/ERβ1 cells were increased 12.9 times respectively compared with parental cells (P<0.05). Western blotting showed that ERβ1 protein levels were also increased correspondingly. Cell experiment showed that high dose (10 μmol/L) of RAL inhibited proliferation of all MDA-MB-231 sub-lines, and the greater extent was observed when ERβ1 over-expressed (F=9.273, P=0.015).

Conclusion

The sensitivity to RAL for breast cancer cell of MDA-MB-231 can be increased by up-regulating ERβ1 level.

图1 慢病毒表达框架示意图
表1 Real time PCR引物序列
图2 慢病毒感染MDA-MB-231细胞后绿色荧光表达效率观察(×200)
图3 实时定量PCR检测MDA-MB-231各细胞亚型ERβ1 mRNA和ERα mRNA的相对表达量 *与空白对照组及阴性转染组比较,P<0.05
表2 各组细胞株Western blotting实验定量方差分析结果(±s
图4 Western blotting检测慢病毒转染后各组ERα和ERβ1蛋白表达的变化 1组为阳性转染组MDA-MB-231/ERβ1细胞,2组为阴性转染组MDA-MB-231/eGFP细胞,3组为空白对照组MDA-MB-231细胞
表3 各组细胞株RAL培养增殖率方差分析结果(%,±s
图5 流式细胞术测定 高浓度(10 μmol/L)的RAL对MDA-MB-231的细胞增殖有明显的抑制作用,低浓度(1 μmol/L)对三组细胞均无明显抑制作用
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2]
Fan L, Strasser WK, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289.
[3]
Shanle EK, Onitilo AA, Huang W, et al. Prognostic significance of full-length estrogen receptor beta expression in stage Ⅰ-Ⅲ triple negative breast cancer[J]. Am J Transl Res, 2015, 7(7): 1246-1259.
[4]
Rosin G, de Boniface J, Karthik GM, et al. Oestrogen receptors beta1 and betacx have divergent roles in breast cancer survival and lymph node metastasis[J]. Br J Cancer, 2014, 111(5): 918-926.
[5]
Sismondi P, D'Alonzo M, Pecchio S, et al. Chemoprevention or mastectomy for women at high risk of developing breast cancer[J]. Maturitas, 2015, 82(3): 271-273.
[6]
Tu ZZ, Ma YX, Tian JM, et al. Estrogen receptor β potentiates the anti-proliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells[J]. J Cancer Res Clin, 2012,138(7): 1091-1103.
[7]
Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the nurses’ health study[J]. Mod Pathol, 2010, 23(2): 197-204.
[8]
Tan W, Li Q, Chen K, et al. Estrogen receptor beta as a prognostic factor in breast cancer patients: a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(9): 121-127.
[9]
Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC)[J]. Ann Oncol, 2013, 24(8): 1986-1993.
[10]
Hou YF, Yuan ST, Li HC, et al. ERbeta exerts multiple stimulative effects on human breast carcinoma cells[J]. Oncogene, 2004, 23(34): 5799-5806.
[11]
Kim SH, Kim KY, Yu SN, et al. Autophagy inhibition enhances silibinin-induced apoptosis by regulating reactive oxygen species production in human prostate cancer PC-3 cells[J]. Biochem Biophys Res Comun, 2015, 468(1-2): 151-156.
[12]
Zheng N, Zhang P, Huang H, et al. ERα down-regulation plays a key role in silibinin-induced autophagy and apoptosis in human breast cancer MCF-7 cells[J]. J Pharmacol Sci, 2015, 128(3): 97-107.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要